Categories: BioTechHealthTechMedTech
Summary:
Cara Therapeutics is a biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions.
Investors 4
Funding Rounds 1
Date | Series | Amount | Investors |
21.07.2010 | Series D | $15M | - |
Mentions in press and media 10
Date | Title | Description | Source |
07.03.2024 | Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual... | - | globenewsw... |
02.11.2023 | Cara Therapeutics Announces up to $40.0 Million Non-Dilutive... | - | globenewsw... |
25.02.2022 | Kapruvia® receives positive CHMP opinion for the treatment o... | Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefali... | globenewsw... |
03.01.2018 | Centrexion’s $67M Series D round to fund Phase 3 pain studie... | Despite being just four years old, Centrexion is building a significant pipeline of non-opioid, non-... | medcitynew... |
30.06.2017 | Cara Therapeutics: A lesson in clinical trial failure and sp... | Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill... | statnews.c... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
21.07.2010 | Cara Therapeutics Raises $15m in Series D Financing | Cara Therapeutics, Inc., a Shelton, CT-based biotechnology company focused on developing novel thera... | finsmes.co... |
27.09.2007 | Life sciences briefing: Thursday, Sept. 27, 2007 | Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium Internat... | venturebea... |
- | Stocks making the biggest moves midday: Best Buy, Palo Alto ... | Check out the companies making headlines in midday trading.
Best Buy — The electronics retailer’s sh... | cnbc.com/2... |
- | Centrexion’s $67M Series D round to fund Phase 3 pain studie... | Boston-based Centrexion Therapeutics has finalized $67 million in Series D financing to fund upcomin... | medcitynew... |
Reviews 0